Whitfield Dianne C. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Jan 6, 2026
Insider Transaction Report
Form 4
Whitfield Dianne C.
Chief Human Resources Officer
Transactions
- Sale
Common Stock
2026-01-02$80.09/sh−5,715$457,714→ 33,243 total - Sale
Common Stock
2026-01-02$80.71/sh−8,122$655,527→ 25,121 total - Sale
Common Stock
2026-01-02$81.90/sh−835$68,387→ 24,286 total - Sale
Common Stock
2026-01-02$82.93/sh−893$74,056→ 23,393 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
- [F2]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $79.42 to $80.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.42 to $81.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.68 to $82.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.82 to $83.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.